CONTENTS

PREFACE xv
FOREWORD xix
CONTRIBUTORS xxi

1 AN OVERVIEW 1
Jack Y. Zheng

1.1 The Drug Discovery and Development Process 2
1.2 Challenges and Strategies in Development of Low-Dose Drug Products 10
1.3 Summary 20
Acknowledgments 20
References 20

I CHALLENGES AND STRATEGIES IN FORMULATION DEVELOPMENT OF ORAL LOW-DOSE DRUG PRODUCTS 23

2 CHALLENGES AND STRATEGIES IN FORMULATION DEVELOPMENT OF ORAL SOLID LOW-DOSE DRUG PRODUCTS 25
Jack Y. Zheng

2.1 Introduction 25
2.2 Current Regulatory Environment and its Impact on New Drug Product Development 28
2.3 Challenges in Developing Low-Dose Formulations 31
### CONTENTS

2.4 Manufacturing Platforms for Low-Dose Drug Products 38  
2.5 Use of Experimental Design in Formulation and Process Development 42  
2.6 Containments 44  
2.7 Summary 45  
Acknowledgments 46  
References 46  

3 PARTICLE SIZE OF DRUG SUBSTANCE AND PRODUCT CONTENT UNIFORMITY—THEORETICAL CONSIDERATIONS 49  
Kevin C. Johnson  
3.1 Introduction 49  
3.2 Concept of Ideal Mixing 50  
3.3 Ideal Mixing Model Comparison with the Yalkowsky and Bolton Approach 56  
3.4 Experimental Support of Model Assumptions 59  
3.5 Analytical and Practical Considerations 61  
References 62  

4 DEVELOPMENT OF LOW-DOSE FORMULATIONS USING FLUIDIZED BED GRANULATION 63  
J. Joe Zhou and Ralph Lipp  
4.1 Introduction 63  
4.2 Granulation Fundamentals 66  
4.3 Theory of Fluidization 68  
4.4 Formulation Development 72  
4.5 Process Development 77  
4.6 Summary 86  
References 86  

5 DEVELOPMENT OF LOW-DOSE SOLID ORAL FORMULATIONS USING WET GRANULATION 89  
Ahmad Almaya  
5.1 Introduction 89  
5.2 Granulation Mechanisms 91  
5.3 General Considerations on Wet Granulation 93  
5.4 Advantages and Disadvantages of Wet Granulation 100  
5.5 Use of Wet Granulation for Low-Dose Formulations 101  
5.6 Process-Induced Form Changes in Wet Granulation 109  
5.7 Concluding Remarks 111  
References 112
8.5  Emerging Technologies and Future Directions 219
Acknowledgments 219
References 219

9  FUNCTION, QUALITY, AND REGULATIONS OF PHARMACEUTICAL EXCIPIENTS FOR ORAL SOLID DOSAGE FORMS 223
Jack Y. Zheng

9.1  Introduction 223
9.2  Classification of Pharmaceutical Excipients in Solid Dosage Forms 224
9.3  Physicochemical Attributes of Pharmaceutical Excipients 225
9.4  Regulatory Status and Excipient Quality 228
9.5  Summary 235
Acknowledgments 235
References 236

II  CHALLENGES IN ANALYTICAL METHOD DEVELOPMENT FOR ORAL LOW-DOSE DRUG PRODUCTS 239

10  ANALYTICAL METHOD DEVELOPMENT: CHALLENGES AND SOLUTIONS FOR LOW-DOSE ORAL DOSAGE FORMS 241
Beverly Nickerson, Reena M. Joseph, Charles Palmer, Alex M. Opio, and George H. Beresford

10.1  Introduction 241
10.2  Case Study 1: Drug Adsorption to Surfaces 242
10.3  Case Study 2: Challenges Due to Nondrug-Related Impurities 245
10.4  Case Study 3: HPLC Purity Method Development Challenges for a Fixed Combination Product Containing a Low-Dose Active Ingredient and a High-Dose Active Ingredient 250
10.5  Case Study 4: Small Volume Dissolution Testing 255
10.6  Summary 261
Acknowledgments 261
References 261

11  IN VITRO DISSOLUTION TESTING AND METHOD DEVELOPMENT 265
Vivian A. Gray, Jack Y. Zheng, and Norman N. Sesi

11.1  Introduction 265
11.2  Overview of Dissolution Testing 265
11.3 Dissolution Method Development
11.4 Dissolution Method Development for Low-Dose Oral Drug Products
11.5 Summary
References

12 ANALYSIS OF PHYSICAL TRANSFORMATION OF API DURING MANUFACTURE AND STORAGE

Gregory A. Stephenson

12.1 Introduction
12.2 Discussion of Solid-State Forms
12.3 Monitoring Processing Steps
12.4 Measuring Transitions and Solid-Form Transformations in the Low-Dose Tablet
12.5 Common Methods Used for Examination of Solid Forms
12.6 Conclusions
References

13 PHYSICAL CHARACTERIZATION TESTS FOR DRUG SUBSTANCES USED IN LOW-DOSE FORMULATIONS

Ronald G. Iacocca

13.1 General Issues in the Physical Characterization of Micronized Powders Used in Low-Dose Formulations
13.2 Particle Size Analysis
13.3 Specific Surface Area Analysis
13.4 Summary
References

14 AN EXCIPIENT LIBRARY APPROACH TO ANALYTICAL DEVELOPMENT FOR LOW-DOSE, SOLID ORAL DOSAGE FORM DRUG PRODUCTS

Qing Chang, Lisheng Kang, Keri Varner, Joyce Bridges, Norman Sesi, and Margo Palmieri

14.1 Introduction
14.2 Importance of Excipient Absorbance Background to Low-Dose Impurity Analysis
14.3 Factors Affecting Excipient Absorbance Background
14.4 Use of Excipient Library
17.4 Handling Potent Compounds in a Containment Laboratory 411
17.5 Additional Considerations for Handling Potent Materials 426
17.6 Summary 427
Acknowledgments 428
References 428

IV REGULATORY CONSIDERATIONS IN THE DEVELOPMENT OF LOW-DOSE DRUG PRODUCTS 429

18 REGULATORY CONSIDERATIONS IN THE DEVELOPMENT OF LOW-DOSE SOLID ORAL DRUG PRODUCTS 431
Ravi S. Harapanhalli

18.1 Introduction and Overview 431
18.2 Three-Pronged Approach to Low-Dose Formulations 433
18.3 Pharmaceutical Development Report 434
18.4 Facility Controls for Highly Potent Drugs 451
18.5 Conclusion 452
References 453

INDEX 455